Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study

• Main Authors: Shan Pan (Author), Teresa Tsakok (Author), Nick Dand (Author), Dagan O. Lonsdale (Author), Floris C. Loeff (Author), Karien Bloem (Author), Annick deVries (Author), David Baudry (Author), Michael Duckworth (Author), Satveer Mahil (Author), Angela Pushpa‐Rajah (Author), Alice Russell (Author), Ali Alsharqi (Author), Gabrielle Becher (Author), Ruth Murphy (Author), Shyamal Wahie (Author), Andrew Wright (Author), Christopher E.M. Griffiths (Author), Nick J. Reynolds (Author), Jonathan Barker (Author), Richard B. Warren (Author), A. David Burden (Author), Theo Rispens (Author), Joseph F. Standing (Author), Catherine H. Smith (Author), on behalf of the BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium (Author)
• Format: Book
• Published: Wiley, 2020-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real‐world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the first‐line therapeutic antibody ustekinumab. The impact of di...